You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 19, 2024

Claims for Patent: 10,507,244


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,507,244
Title:Anti-TIGIT antigen-binding proteins and methods of use thereof
Abstract: Provided herein are antigen-binding proteins (ABPs) that selectively bind to TIGIT and its isoforms and homologs, and compositions comprising the ABPs. Also provided are methods of using the ABPs, such as therapeutic and diagnostic methods.
Inventor(s): Hicklin; Daniel (Montclair, NJ), Winston; William (Marlborough, MA), Seidel-Dugan; Cynthia (Belmont, MA), Nielson; Nels P. (Lebanon, NH)
Assignee: Potenza Therapeutics, Inc. (Cambridge, MA)
Application Number:15/627,161
Patent Claims:1. A method of enhancing an immune response in a human subject in need thereof, comprising administering to the subject an effective amount of an isolated antibody that specifically binds human TIGIT (hTIGIT; SEQ ID NO: 1), comprising a heavy chain variable (VH) domain comprising from N-terminus to C-terminus, CDR-H1, CDR-H2, and CDR-H3; and a light chain variable (VL) domain comprising from N-terminus to C-terminus CDR-L1, CDR-L2, and CDR-L3, wherein the CDRs of the VH and VL comprise the following six CDR sequences: (a) a CDR-H3 having the sequence A-R-D-G-V-L-X.sub.1-L-N-K-R-S-F-D-I, wherein X.sub.1 is A or T (SEQ ID NO: 128); (b) a CDR-H2 having the sequence S-I-Y-Y-S-G-X.sub.2-T-Y-Y-N-P-S-L-K-S, wherein X.sub.2 is S, Q or G (SEQ ID NO: 129); (c) a CDR-H1 having the sequence G-S-I-X.sub.3-S-G-X.sub.4-Y-Y-W-G, wherein X.sub.3 is E or A, and X.sub.4 is L, V or S (SEQ ID NO: 130); (d) a CDR-L3 having the sequence QQHTVRPPLT (SEQ ID NO: 64); (e) a CDR-L2 having the sequence GASSRAT (SEQ ID NO: 68); and (f) a CDR-L1 having the sequence RASQSVSSSYLA (SEQ ID NO: 71), or a pharmaceutical composition thereof, and further comprising administering at least one additional therapeutic agent.

2. The method of claim 1, wherein the antibody comprises: (a) a CDR-H3 of SEQ ID NO: 32, a CDR-H2 of SEQ ID NO: 40, a CDR-H1 of SEQ ID NO: 54, a CDR-L3 of SEQ ID NO: 64, a CDR-L2 of SEQ ID NO: 68, and a CDR-L1 of SEQ ID NO: 71; (b) a CDR-H3 of SEQ ID NO: 31, a CDR-H2 of SEQ ID NO: 40, a CDR-H1 of SEQ ID NO: 54, a CDR-L3 of SEQ ID NO: 64, a CDR-L2 of SEQ ID NO: 68, and a CDR-L1 of SEQ ID NO: 71; (c) a CDR-H3 of SEQ ID NO: 31, a CDR-H2 of SEQ ID NO: 39, a CDR-H1 of SEQ ID NO: 51, a CDR-L3 of SEQ ID NO: 64, a CDR-L2 of SEQ ID NO: 68, and a CDR-L1 of SEQ ID NO: 71; (d) a CDR-H3 of SEQ ID NO: 31, a CDR-H2 of SEQ ID NO: 40, a CDR-H1 of SEQ ID NO: 52, a CDR-L3 of SEQ ID NO: 64, a CDR-L2 of SEQ ID NO: 68, and a CDR-L1 of SEQ ID NO: 71; or (e) a CDR-H3 of SEQ ID NO: 31, a CDR-H2 of SEQ ID NO: 41, a CDR-H1 of SEQ ID NO: 53, a CDR-L3 of SEQ ID NO: 64, a CDR-L2 of SEQ ID NO: 68, and a CDR-L1 of SEQ ID NO: 71.

3. The method of claim 1, wherein the antibody that specifically binds human TIGIT is MAB6, MAB7, MAB8, MAB9, MAB10, MAB11, or MAB12, wherein MAB6 comprises a VH domain of SEQ ID NO: 9, and a VL domain of SEQ ID NO: 26; MAB7 comprises a VH domain of SEQ ID NO: 10, and a VL domain of SEQ ID NO: 26; MAB8 comprises a VH domain of SEQ ID NO: 11, and a VL domain of SEQ ID NO: 26; MAB9 comprises a VH domain of SEQ ID NO: 12, and a VL domain of SEQ ID NO: 26; MAB10 comprises a VH domain of SEQ ID NO: 13, and a VL domain of SEQ ID NO: 26: MAB11 comprises a VH domain of SEQ ID NO: 14, and a VL domain of SEQ ID NO: 26; and MAB12 comprises a VH domain of SEQ ID NO: 15, and a VL domain of SEQ ID NO: 26.

4. The method of claim 1, wherein the antibody that specifically binds human TIGIT is MAB10, wherein MAB10 comprises a VH domain of SEQ ID NO: 13, and a VL domain of SEQ ID NO: 26.

5. The method of claim 1, wherein the at least one additional therapeutic agent is an agent that inhibits the interaction between PD-1 and PD-L, and wherein the agent that inhibits the interaction between PD-1 and PD-L1 is selected from an antibody, a peptidomimetic, or a small molecule.

6. The method of claim 5, wherein the agent that inhibits the interaction between PD-1 and PD-L1 is selected from the group consisting of pembrolizumab, nivolumab, atezolizumab, avelumab, durvalumab and BMS-936559.

7. The method of claim 1, wherein the subject is a subject that has been treated with an agent that inhibits the interaction between PD-1 and PD-L1 prior to performing such method.

8. The method of claim 1, wherein the subject was not responsive to a prior therapy with the at least one additional therapeutic agent.

9. The method of claim 1, wherein the additional therapeutic agent is an immunostimulatory agent selected from (a) an agent that blocks signaling of an inhibitory receptor of an immune cell or a ligand thereof; (b) an agonist to a stimulatory receptor of an immune cell; (c) a cytokine; (d) an oncolytic virus; (e) a T cell expressing a chimeric antigen receptor; (f) a bi- or multi-specific T cell directed antibody; (g) an anti-TGF-.beta. antibody; (h) a TGF-.beta. trap; (i) a vaccine to a cancer-associated antigen, including such antigen or a nucleic acid encoding such antigen and (j) combinations thereof.

10. The method of claim 9, wherein the additional therapeutic agent is an agent that blocks signaling of an inhibitory receptor of an immune cell or a ligand thereof, and the inhibitory receptor or ligand thereof is selected from CTLA-4, PD-L2, LAG-3, Tim3, neuritin, BTLA, CECAM-1, CECAM-5, VISTA, LAIR1, CD160, 2B4, TGF-R, KIR, and combinations thereof.

11. The method of claim 9, wherein the additional therapeutic agent is an agonist to a stimulatory receptor of an immune cell, and the stimulatory receptor of an immune cell is selected from OX40, CD2, CD27, CDS, ICAM-1, LFA-1 (CD11a/CD18), ICOS (CD278), 4-1BB (CD137), GITR, CD28, CD30, CD40, BAFFR, HVEM, CD7, LIGHT, NKG2C, SLAMF7, NKp80, CD160, B7-H3, CD83 ligand, and combinations thereof.

12. A method of treating a cancer in a human subject in need thereof, comprising administering to the subject an effective amount of an isolated antibody that specifically binds human TIGIT (hTIGIT; SEQ ID NO: 1), comprising a heavy chain variable (VH) domain comprising from N-terminus to C-terminus, CDR-H1, CDR-H2, and CDR-H3; and a light chain variable (VL) domain comprising from N-terminus to C-terminus CDR-L1, CDR-L2, and CDR-L3, wherein the CDRs of the VH and VL comprise the following six CDR sequences: (a) a CDR-H3 having the sequence A-R-D-G-V-L-X.sub.1-L-N-K-R-S-F-D-I, wherein X.sub.1 is A or T (SEQ ID NO: 128); (b) a CDR-H2 having the sequence S-I-Y-Y-S-G-X.sub.2-T-Y-Y-N-P-S-L-K-S, wherein X.sub.2 is S, Q or G (SEQ ID NO: 129); (c) a CDR-H1 having the sequence G-S-I-X.sub.3-S-G-X.sub.4-Y-Y-W-G, wherein X.sub.3 is E or A, and X.sub.4 is L, V or S (SEQ ID NO: 130); (d) a CDR-L3 having the sequence QQHTVRPPLT (SEQ ID NO: 64); (e) a CDR-L2 having the sequence GASSRAT (SEQ ID NO: 68); and (f) a CDR-L1 having the sequence RASQSVSSSYLA (SEQ ID NO: 71); and further comprising administering at least one additional therapeutic agent selected from an immunomodulatory agent, a chemotherapeutic agent, an immunostimulatory agent, radiation, and combinations thereof.

13. The method of claim 12, wherein the immunomodulatory agent comprises an agent that inhibits the interaction between PD-1 and PD-L1, and wherein the agent that inhibits the interaction between PD-1 and PD-L1 is selected from an antibody, a peptidomimetic, or a small molecule.

14. The method of claim 13, wherein the agent that inhibits the interaction between PD-1 and PD-L1 is selected from the group consisting of pembrolizumab, nivolumab, atezolizumab, avelumab, durvalumab, and BMS-936559.

15. The method of claim 12, wherein the antibody that specifically binds human TIGIT comprises: (a) a CDR-H3 of SEQ ID NO: 32, a CDR-H2 of SEQ ID NO: 40, a CDR-H1 of SEQ ID NO: 54, a CDR-L3 of SEQ ID NO: 64, a CDR-L2 of SEQ ID NO: 68, and a CDR-L1 of SEQ ID NO: 71; (b) a CDR-H3 of SEQ ID NO: 31, a CDR-H2 of SEQ ID NO: 40, a CDR-H1 of SEQ ID NO: 54, a CDR-L3 of SEQ ID NO: 64, a CDR-L2 of SEQ ID NO: 68, and a CDR-L1 of SEQ ID NO: 71; (c) a CDR-H3 of SEQ ID NO: 31, a CDR-H2 of SEQ ID NO: 39, a CDR-H1 of SEQ ID NO: 51, a CDR-L3 of SEQ ID NO: 64, a CDR-L2 of SEQ ID NO: 68, and a CDR-L1 of SEQ ID NO: 71; (d) a CDR-H3 of SEQ ID NO: 31, a CDR-H2 of SEQ ID NO: 40, a CDR-H1 of SEQ ID NO: 52, a CDR-L3 of SEQ ID NO: 64, a CDR-L2 of SEQ ID NO: 68, and a CDR-L1 of SEQ ID NO: 71; or (e) a CDR-H3 of SEQ ID NO: 31, a CDR-H2 of SEQ ID NO: 41, a CDR-H1 of SEQ ID NO: 53, a CDR-L3 of SEQ ID NO: 64, a CDR-L2 of SEQ ID NO: 68, and a CDR-L1 of SEQ ID NO: 71.

16. The method of claim 12, wherein the antibody that specifically binds human TIGIT is MAB6, MAB7, MAB8, MAB9, MAB10, MAB11, OR MAB12, wherein MAB6 comprises a VH domain of SEQ ID NO: 9, and a VL domain of SEQ ID NO: 26; MAB7 comprises a VH domain of SEQ ID NO: 10, and a VL domain of SEQ ID NO: 26; MAB8 comprises a VH domain of SEQ ID NO: 11, and a VL domain of SEQ ID NO: 26; MAB9 comprises a VH domain of SEQ ID NO: 12, and a VL domain of SEQ ID NO: 26; MAB10 comprises a VH domain of SEQ ID NO: 13, and a VL domain of SEQ ID NO: 26: MAB11 comprises a VH domain of SEQ ID NO: 14, and a VL domain of SEQ ID NO: 26; and MAB12 comprises a VH domain of SEQ ID NO: 15, and a VL domain of SEQ ID NO: 26.

17. The method of claim 12, wherein the antibody that specifically binds human TIGIT is MAB10, wherein MAB10 comprises a VH domain of SEQ ID NO: 13, and a VL domain of SEQ ID NO: 26.

18. The method of claim 12, wherein the subject is a subject that has been treated with an agent that inhibits the interaction between PD-1 and PD-L1 prior to performing such method.

19. The method of claim 12, wherein the cancer in the subject was not responsive to a prior therapy with the at least one additional therapeutic agent.

20. The method of claim 12, wherein at least one additional therapeutic agent is an agent selected from a chemotherapeutic agent, an immunostimulatory agent, radiation, and combinations thereof.

21. The method of claim 12, wherein the antibody that specifically binds human TIGIT is MAB10, wherein MAB10 comprises a VH domain of SEQ ID NO: 13, and a VL domain of SEQ ID NO: 26, and wherein the immunomodulatory agent comprises an agent that inhibits the interaction between PD-1 and PD-L1 selected from the group consisting of an antibody, a peptidomimetic, and a small molecule.

22. The method of claim 21, wherein the agent that inhibits the interaction between PD-1 and PD-L1 is selected from the group consisting of pembrolizumab, nivolumab, atezolizumab, avelumab, durvalumab, and BMS-936559.

23. The method of claim 22, wherein the agent that inhibits the interaction between PD1 and PD-L1 is pembrolizumab.

24. The method of claim 22, wherein the agent that inhibits the interaction between PD1 and PD-L1 is nivolumab.

Details for Patent 10,507,244

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. KEYTRUDA pembrolizumab For Injection 125514 09/04/2014 ⤷  Try a Trial 2035-10-01
Merck Sharp & Dohme Corp. KEYTRUDA pembrolizumab Injection 125514 01/15/2015 ⤷  Try a Trial 2035-10-01
Bristol-myers Squibb Company OPDIVO nivolumab Injection 125554 12/22/2014 ⤷  Try a Trial 2035-10-01
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.